Pharmaceuticals

Global Polivy Market 2026–2030: Forecast Insights for Business Planning

March 6, 2026March 8, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the polivy market from 2026–2035 with trusted insights from The Business Research Company

What size range is anticipated for the Polivy Market from 2026 to 2030?

Historical growth was propelled by a surge in the prevalence of diffuse large b-cell lymphoma, coupled with strides in monoclonal antibody development, the increasing number of oncology treatment centers, a growing embrace of targeted cancer therapies, and refined diagnostic capabilities.

Projected growth in the forecast period is attributable to heightened demand for personalized oncology drugs, escalating investments in antibody-drug conjugate (ADC) research pipelines, the broader deployment of first-line combination therapies, an intensified focus on treatment-resistant lymphomas, and increasing regulatory approvals for targeted biologics. Concurrently, major trends anticipated during this period encompass the expanding adoption of antibody-drug conjugates, their rising application in targeted lymphoma therapies, growing integration with combination chemotherapy regimens, an expansion of precision oncology treatments, and an enhanced emphasis on CD79b-targeted drugs.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20183&type=smp

What Drivers Are Affecting Demand In The Polivy Market?

The expanding prevalence of diffuse large B-cell lymphoma is projected to drive the Polivy market’s growth moving forward. Diffuse large B-cell lymphoma (DLBCL), identified as the predominant type of non-hodgkin lymphoma (NHL), is an aggressive blood cancer originating from B-lymphocytes, vital white blood cells for the immune system’s antibody production against infections. This rise in DLBCL cases stems from factors such as an aging demographic, increased rates of immunosuppression due to conditions like HIV/AIDS and organ transplants, and various environmental exposures contributing to its development. Polivy, when used with chemotherapy, is indicated for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in patients who have undergone prior therapies. As an illustration, in July 2024, a report from the Royal College of Pathologists, a UK-based professional membership body, indicated that approximately 5,500 individuals are diagnosed annually with diffuse large B-cell lymphoma (DLBCL), a highly aggressive non-Hodgkin lymphoma, in the UK. Roughly 30% of these patients experience refractory disease or a relapse soon after their initial treatment. Consequently, the increasing incidence of diffuse large B-cell lymphoma is fueling the Polivy market’s expansion.

Which Segment Groups Are Influencing The Polivy Market?

The polivy market covered in this report is segmented –

1) By Indication: Previously Untreated Diffuse Large B-Cell Lymphoma, Relapsed Or Refractory Diffuse Large B-Cell Lymphoma

2) By Dosage Form: Injectable Solution

3) By Distribution Channel: Direct Sales, Pharmaceutical Wholesalers, Online Pharmacies

Which Trends Are Expected To Influence The Polivy Market In The Upcoming Years?

Companies operating in the polivy market are concentrating on creating innovative regimens, such as first-line antibody-drug conjugate (ADC) combinations, to more effectively target aggressive B-cell lymphomas and enhance patient outcomes. An initial ADC combination merges a monoclonal antibody that selectively attaches to tumor-specific proteins with a cytotoxic agent, enabling highly precise therapy, unlike traditional chemotherapy which impacts both malignant and healthy cells. For instance, in April 2023, Genentech, a U.S.-based biotechnology company, secured FDA approval for Polivy (polatuzumab vedotin-piiq) when used with R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) for previously untreated diffuse large B-cell lymphoma (DLBCL) in adults. Polivy stands as a pioneering anti-CD79b ADC, created leveraging Seagen’s linker-payload technology: its antibody targets the CD79b protein found on B-cells, the attached payload (vedotin) serves as a potent microtubule-disrupting substance, and once bound, the drug enters the cancer cell where the cytotoxic agent is released to prompt cell death. Its distinctive characteristics encompass significant specificity for malignant B-cells, a more favorable safety profile compared to systemic chemotherapy, and a demonstrated 27% decrease in the likelihood of progression or fatality versus standard R-CHOP, as shown in the crucial POLARIX study. This combined therapy is now set to revolutionize initial treatment for DLBCL, potentially lowering relapse incidences and lessening the prolonged burden on patients.

Who Are The Primary Competitors In The Global Polivy Market?

Major companies operating in the polivy market are F. Hoffmann-La Roche Ltd (Genentech Inc.)

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/polivy-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Polivy Market?

North America was the largest region in the polivy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the polivy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Polivy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20183&type=smp

Browse Through More Reports Similar to the Global Polivy Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Trade Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-finance-global-market-report

Hypermarkets Market Report 2026

https://www.thebusinessresearchcompany.com/report/hypermarkets-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795